Erasca (NASDAQ:ERAS - Get Free Report) will likely be posting its Q4 2024 quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect Erasca to post earnings of ($0.12) per share for the quarter.
Erasca (NASDAQ:ERAS - Get Free Report) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. During the same period in the prior year, the firm earned ($0.20) EPS. On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Erasca Price Performance
Shares of NASDAQ:ERAS traded up $0.05 during trading on Friday, hitting $1.53. 8,896,958 shares of the company's stock were exchanged, compared to its average volume of 1,726,079. The business's 50-day simple moving average is $1.63 and its 200 day simple moving average is $2.37. The company has a market cap of $432.57 million, a price-to-earnings ratio of -1.84 and a beta of 1.22. Erasca has a 52-week low of $1.23 and a 52-week high of $3.45.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on ERAS. The Goldman Sachs Group reduced their price objective on shares of Erasca from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Friday. Morgan Stanley restated an "overweight" rating and set a $4.00 price objective on shares of Erasca in a research report on Friday, March 7th. Bank of America raised Erasca from a "neutral" rating to a "buy" rating and set a $5.00 price objective on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Erasca in a research report on Friday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Erasca has a consensus rating of "Buy" and an average target price of $4.80.
Check Out Our Latest Analysis on ERAS
About Erasca
(
Get Free Report)
Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
Featured Articles
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
